• Monday, Nov 29, 2021
  • Last Update : 01:49 am

Second J&J Covid shot gets expert backing; FDA looking at lowering age for Pfizer booster

  • Published at 01:38 pm October 16th, 2021
J&J
File photo: A box of Johnson & Johnson's Covid-19 vaccines is seen at the Forem vaccination centre in Pamplona, Spain, April 22, 2021 Reuters

J&J scientists say their vaccine is more durable than the mRNA vaccines

Outside advisers to the US Food and Drug Administration on Friday unanimously recommended the agency authorize a second shot of Johnson & Johnson's Covid-19 vaccine for all recipients of the one-dose inoculation.

The agency is also considering lowering the recommended age for booster shots of the Pfizer/BioNTech vaccine to people as young as 40, FDA official Dr Peter Marks told the advisory panel.

The FDA's Vaccines and Related Biological Products Advisory Committee backed the shots for all J&J recipients aged 18 and older at least two months after their first dose.

The FDA is not bound to follow the recommendation, but typically does.

After hearing presentations from J&J and FDA scientists, many members of the advisory panel asked if J&J's single-dose vaccine should actually be considered a two-dose shot for everyone.

They pointed to the lower levels of virus neutralizing antibodies it provokes compared to vaccines using messenger RNA (mRNA) technology from Moderna Inc and Pfizer/BioNTech.

"There is a public health imperative. What we're seeing is this is a group with overall lower efficacy than we have seen with the mRNA vaccine, and so there is some urgency to do something," said Dr Arnold Monto, an epidemiologist at the University of Michigan's School of Public Health who chaired the meeting.


Also read - Study: Moderna or Pfizer booster dose works better for people vaccinated with J&J vaccine


The FDA authorized boosters of the Pfizer/BioNTech vaccine last month for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.

Marks, director of the FDA's Center for Biologics Evaluation and Research, said data from Israel, where Pfizer booster shots have already been administered broadly, suggests that the vaccine's efficacy is waning and makes a compelling case for lowering the age for receiving booster shots to 40.

Concerns about rare cases of heart inflammation in younger men who receive the Pfizer/BioNTech vaccine also made 40 a good cut-off point for the additional shots, Marks said.

Concerns over J&J data

Marks raised concerns that the data presented by J&J did not reflect all of the information on the vaccine's performance.

"There are some real challenges here. All of the data do not fully align with this being a vaccine that retains excellent activity over time, against all forms of disease or even against severe forms of disease," Marks said.

J&J scientists said their vaccine was more durable than the mRNA vaccines.

"If the vaccine isn't adequate, it should be boosted and everybody should get it," said Dr Eric Rubin, an infectious disease expert at the Harvard Chan School of Public Health.

After the vote, Rubin said he expects that getting the second J&J dose later than two months after the first should be safe. While the data are scarce, he said, "there isn't much to suspect that it's wrong," adding: "I certainly am supportive of those individuals getting another dose."

Once the FDA signs off on the second dose, the US Centers for Disease Control and Prevention will make specific recommendations on who should get the shots. CDC advisers are scheduled to meet to discuss the boosters next week.

On Thursday, the panel unanimously backed booster shots of Moderna's Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.

US health officials have been under pressure to authorize the additional shots after the White House announced plans in August for a widespread booster campaign pending approvals from the FDA and the CDC.

52
Facebook 51
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail